Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: Review of the current literature

Current Opinion in Oncology

Volumn 25, Issue 3, 2013, Pages 224-228

  Granata, Roberta ^a   Locati, Laura ^a   Licitra, Lisa ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

metastatic ATC; molecular target; new therapies

Indexed keywords

AURORA KINASE INHIBITOR; B RAF KINASE; BETA CATENIN; BORTEZOMIB; CARBOPLATIN; CHRYSIN; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; EFATUTAZONE; NOTCH1 RECEPTOR; PACLITAXEL; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; SORAFENIB; TOZASERTIB;

ANAPLASTIC THYROID CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL RESEARCH; DISTANT METASTASIS; DRUG EFFICACY; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; GENE THERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; PATHOGENESIS; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STILBENES; THYROID NEOPLASMS;

EID: 84876296798     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835ff44b     Document Type: Review

References (24)

1. Lim SM, Shin SJ, Chung WY, et al. Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Med J 2012; 53:352-357.
2. Smallridge RC. Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2012; 97:2566-2572.
3. Smallridge RC, Abate E. Anaplastic thyroid carcinoma: clinical aspects. In: Wartofsky L, Van Nostrand D, editors. Thyroid cancer: a comprehensive guide to clinical management, 3rd ed. New York: Springer; 2012.
4. Smallridge RC, Ain KB, Asa SL, et al. American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012; 22.
5. Ito K, Hanamura T, Murayama K, et al. Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck 2012; 34:230-237.
6. Sugitani I, Miyauchi A, Sugino K, et al. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg 2012; 36:1247-1254.
7. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12:245-262.
8. Nagaiah G, Hossain A, Mooney CJ, et al. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol 2011; 5423-5458.
9. Hou P, Ji M, Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 2008; 113:2440-2447.
10. Donghi R, Longoni A, Pilotti S, et al. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Investig 1993; 91:1753-1760.
11. Hébrant A, Dom G, Dewaele M, et al. mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch. PLoS One 2012; 7:e37807; doi: 10.1371/journal.pone.0037807. Epub 2012 Oct 24.
12. Wunderlich A, Roth S, Ramaswamy A, et al. Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer. Endocrine 2012; 42:637-646.
13. Mitsiades CS, McMillin D, Kotoula V, et al. Antitumor effects of the protea-some inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 2006; 91:4013-4021.
14. Conticello C, Adamo L, Giuffrida R, et al. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J Clin Endocrinol Metab 2007; 92:1938-1942.
15. Arlot-Bonnemains Y, Baldini E, Martin B, et al. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocr Relat Cancer 2008; 15:559-568.
16. Libertini S, Abagnale A, Passaro C, et al. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947. Endocr Relat Cancer 2011; 18:129-141.
17. Yu XM, Phan T, Patel PN, et al. Chrysin activates Notch1 signaling and suppresses tumor growth of anaplastic thyroid carcinoma in vitro and in vivo. Cancer 2013; 119:774-781.
18. Sosa JA, Elisei R, Jarzab B, et al. A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): final survival analysis for the FACT trial. J Clin Oncol 2011; 29(Suppl):abstr 5502.
19. Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009; 19:233-240.
20. Savvides P, Nagaiah G, Lavertu PN, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 2012. [Epub ahead of print]
21. Bible KC, Suman VJ, Menefee ME, et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab 2012; 97:3179-3184.
22. Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 2011; 71:4403-4411.
23. Mullen JT, Tanabe KK. Viral oncolysis. Oncol 2002; 7:106-119.
24. Reddi HV, Madde P, McDonough SJ. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine nonavid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy. Cancer Gene Ther 2012; 19:659-665.